Travere Therapeutics, Inc. (TVTX)

Market Cap	460.96M
Revenue (ttm)	183.23M
Net Income (ttm)	-161.13M
Shares Out	76.13M
EPS (ttm)	-2.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	833,656
Open	6.67
Previous Close	6.69
Day's Range	6.03 - 6.77
52-Week Range	5.12 - 19.54
Beta	0.69
Analysts	Buy
Price Target	16.58 (+173.6%)
Earnings Date	May 6, 2024

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurrin...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Eric M. Dube Ph.D.
• Employees: 380
• Stock Exchange: NASDAQ
• Ticker Symbol: TVTX

Financial Performance

In 2023, TVTX's revenue was $145.24 million, an increase of 32.69% compared to the previous year's $109.46 million. Losses were -$111.40 million, -60.00% less than in 2022.

Analyst Forecast

According to 14 analysts, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is $16.58, which is an increase of 173.60% from the latest price.

Price Target

$16.58

(173.60% upside)

Analyst Consensus: Buy